• Explore /
  • Poster
  • / Long-term safety and efficacy of lanreotide treatment in Japanese patients with neuroendocrine tumors: Final analysis of a phase II open-label extension study.

Long-term safety and efficacy of lanreotide treatment in Japanese patients with neuroendocrine tumors: Final analysis of a phase II open-label extension study.

Abstract Poster

Authors

null

Tetsuhide Ito

Department of Gastroenterology and Hepatology, International University of Health and Welfare Graduate School of Medicine, Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital, Fukuoka, Japan

Tetsuhide Ito , Seiichi Hisamatsu , Akihiro Nakajima , Akira Shimatsu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

JapicCTI-132375, JapicCTI-142698

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 621)

Abstract #

621

Poster Bd #

G2

Abstract Disclosures

Similar Posters

First Author: Jing Luo

First Author: Wenxi Yu

First Author: Dan Liu

First Author: Kevin Joseph Harrington